Chronic myeloid leukemia with pure erythroid leukemia blast crisis
Chronic myeloid leukemia (CML), a myeloproliferative neoplasm defined by the presence of the BCR-ABL1 oncogene created by the reciprocal translocation t(9;22)(q34.1;q11.2), can often be controlled by medications that inhibit this constitutive tyrosine kinase. However, if these therapies fail, the disease may progress to a form resembling an acute leukemia. While most of these CML 'blast crises' are characterized by blasts with a myeloid (granulocytic) or lymphoid lineage, these blasts may rarely be predominantly erythroid. Cases of CML erythroid blast crises have been reported; however, secondary pure erythroid leukemia arising from a CML blast crisis has only been definitively reported once before. We report the second definitive case of pure erythroid leukemia with the t(9;22)(q34.1;q11.2) presenting as a CML blast crisis and characterize the morphologic, immunophenotypic, flow cytometric, cytogenetic, and molecular findings.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:63 |
|---|---|
| Enthalten in: |
Leukemia & lymphoma - 63(2022), 1 vom: 12. Jan., Seite 212-216 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Jacobs, Jeremy W [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Acute erythroid leukemia |
|---|
| Anmerkungen: |
Date Completed 17.03.2022 Date Revised 17.03.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/10428194.2021.1975191 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM330293362 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM330293362 | ||
| 003 | DE-627 | ||
| 005 | 20231225210953.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/10428194.2021.1975191 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1100.xml |
| 035 | |a (DE-627)NLM330293362 | ||
| 035 | |a (NLM)34486918 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Jacobs, Jeremy W |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Chronic myeloid leukemia with pure erythroid leukemia blast crisis |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 17.03.2022 | ||
| 500 | |a Date Revised 17.03.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Chronic myeloid leukemia (CML), a myeloproliferative neoplasm defined by the presence of the BCR-ABL1 oncogene created by the reciprocal translocation t(9;22)(q34.1;q11.2), can often be controlled by medications that inhibit this constitutive tyrosine kinase. However, if these therapies fail, the disease may progress to a form resembling an acute leukemia. While most of these CML 'blast crises' are characterized by blasts with a myeloid (granulocytic) or lymphoid lineage, these blasts may rarely be predominantly erythroid. Cases of CML erythroid blast crises have been reported; however, secondary pure erythroid leukemia arising from a CML blast crisis has only been definitively reported once before. We report the second definitive case of pure erythroid leukemia with the t(9;22)(q34.1;q11.2) presenting as a CML blast crisis and characterize the morphologic, immunophenotypic, flow cytometric, cytogenetic, and molecular findings | ||
| 650 | 4 | |a Letter | |
| 650 | 4 | |a Pure erythroid leukemia | |
| 650 | 4 | |a acute erythroid leukemia | |
| 650 | 4 | |a blast crisis | |
| 650 | 4 | |a chronic myeloid leukemia | |
| 650 | 4 | |a myeloproliferative neoplasm | |
| 700 | 1 | |a Ramaswamy, Rahul |e verfasserin |4 aut | |
| 700 | 1 | |a States, Vanessa |e verfasserin |4 aut | |
| 700 | 1 | |a Reppucci, Jennifer |e verfasserin |4 aut | |
| 700 | 1 | |a Oluwole, Olalekan O |e verfasserin |4 aut | |
| 700 | 1 | |a Mason, Emily F |e verfasserin |4 aut | |
| 700 | 1 | |a Thompson, Mary Ann |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Leukemia & lymphoma |d 1989 |g 63(2022), 1 vom: 12. Jan., Seite 212-216 |w (DE-627)NLM012624047 |x 1029-2403 |7 nnns |
| 773 | 1 | 8 | |g volume:63 |g year:2022 |g number:1 |g day:12 |g month:01 |g pages:212-216 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/10428194.2021.1975191 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 63 |j 2022 |e 1 |b 12 |c 01 |h 212-216 | ||